Novavax along with its partner Serum Institute of India (SII) has sought the World Health Organization's approval for emergency use listing (EUL) of its Covid-19 vaccine, said the company in a statement on Thursday. "Today's submission of our protein-based Covid-19 vaccine to WHO for emergency use listing is a significant step on the path to accelerating access and more equitable distribution to countries in great need around the world," said Stanley C Erck, the president and chief executive officer of Novavax. “It represents another major milestone in Novavax' transformation into a commercial global vaccine company and reinforces the value of global collaboration and need for multiple approaches to help control the pandemic," he added.